Kiniksa Pharmaceuticals International, plc (KNSA) director sells and gifts shares

Rhea-AI Filing Summary

Cole G Bradley, a director of Kiniksa Pharmaceuticals International, plc, reported two share dispositions on 29 July 2026. He sold 3,673 Class A Ordinary Shares at $81.43 per share and made a bona fide gift of 4,500 shares to a donor advised fund. The Rule 10b5-1 trading plan box was not checked.

Insider Trade Summary

Net Seller: 8,173 shares

Net Sell 2 txns

Insider Cole G Bradley

Role Director

Sold 3,673 shs ($299K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Share	3,673	$81.43	$299K
Gift	Class A Ordinary Share F1	4,500	$0.00	$0.00

Holdings After Transaction: Class A Ordinary Share — 7,172 shares (Direct)

Footnotes (1)

1. F1. This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.

Key Figures

Shares sold: 3,673 Class A Ordinary Shares Sale price per share: $81.43 Shares gifted: 4,500 Class A Ordinary Shares

3 metrics

Shares sold 3,673 Class A Ordinary Shares Non-derivative sale on 2026-07-29 by director Cole G Bradley

Sale price per share $81.43 Price per Class A Ordinary Share in the 3,673-share sale

Shares gifted 4,500 Class A Ordinary Shares Bona fide gift to a donor advised fund on 2026-07-29

Key Terms

Class A Ordinary Share, bona fide gift, donor advised fund

3 terms

Class A Ordinary Share financial

"security_title: "Class A Ordinary Share" for each reported transaction"

A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.

bona fide gift financial

"This transaction involves a bona fide gift of securities from the reporting person"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

donor advised fund financial

"a bona fide gift of securities from the reporting person to a donor advised fund"

A donor advised fund is a charitable savings account you fund with cash or assets (including stocks) that lets you take an immediate tax benefit while recommending when and which charities receive grants over time. Think of it like a dedicated piggy bank for giving: you get tax relief when you put money in, can avoid selling appreciated securities and triggering capital gains, and still control the timing and recipients of donations, which affects tax planning, portfolio decisions, and public giving signals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 04:35 PM Accepted by SEC EDGAR 07/31/2026 - 04:34 PM Learn about SEC filing dates

FAQ

What insider share transactions did Cole G Bradley report for KNSA?

Cole G Bradley reported disposing of 8,173 KNSA Class A Ordinary Shares in total, including a sale of 3,673 shares at $81.43 per share and a bona fide gift of 4,500 shares to a donor advised fund on 29 July 2026.

How many KNSA shares did Cole G Bradley sell and at what price?

He sold 3,673 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc at a price of $81.43 per share on 29 July 2026, in a non-derivative transaction classified as a sale.

Did Cole G Bradley make any gifts of KNSA shares in this report?

Yes. He made a bona fide gift of 4,500 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc to a donor advised fund. The transaction is recorded with a per-share price of $0.00, reflecting its gift nature.

Were Cole G Bradley’s KNSA share transactions under a Rule 10b5-1 plan?

The report indicates the Rule 10b5-1 trading plan checkbox was not selected. This means the disclosed KNSA share sale and the 4,500-share gift were not affirmatively reported as executed pursuant to a Rule 10b5-1 trading plan.

What types of securities were involved in Cole G Bradley’s KNSA transactions?

Both transactions involved Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc (KNSA). One entry records a market-value sale, and the other records a bona fide gift of the same security class to a donor advised fund.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cole G Bradley

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	07/29/2026		S		3,673	D	$81.43	11,672	D
Class A Ordinary Share	07/29/2026		G(1)		4,500	D	$0	7,172	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.

	/s/ Douglas Barry, Attorney-in-Fact	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)